论文部分内容阅读
目的分析莫沙必利联合埃索美拉唑、思密达治疗反流性食管炎临床疗效。方法将60例反流性食管炎患者随机分为治疗组和对照组,两组均予以莫沙必利,埃索美拉唑口服,治疗组加用思密达口服。结果治疗组和对照组的治愈率分别为70.0%和43.3%,总有效率分别为90.0%和67.7%,两组比较差异有统计学意义(P<0.05)。结论莫沙必利三联疗法治疗反流性食管炎疗效确切,安全可靠,值得临床推广应用。
Objective To analyze the clinical efficacy of mosapride combined with esomeprazole and metmycin in the treatment of reflux esophagitis. Methods Sixty patients with reflux esophagitis were randomly divided into treatment group and control group. Mosapride and esomeprazole were given orally in both groups. The treatment group was given oral treatment with metmyme. Results The cure rates of the treatment group and the control group were 70.0% and 43.3%, respectively. The total effective rates were 90.0% and 67.7% respectively. There was significant difference between the two groups (P <0.05). Conclusion Mosapride triple therapy for the treatment of reflux esophagitis is effective, safe and reliable, and is worthy of clinical application.